These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17340472)

  • 1. On "Composition, Quality Control, and Labeling of Plasma-Derived Products for the Treatment of von Willebrand disease" (Semin Thromb Hemost 2006;32: 529-536).
    Svae TE; Biesert L; Neisser-Svae A; Kannicht C; Römisch J
    Semin Thromb Hemost; 2007 Mar; 33(2):215-6. PubMed ID: 17340472
    [No Abstract]   [Full Text] [Related]  

  • 2. Composition, quality control, and labeling of plasma-derived products for the treatment of von Willebrand disease.
    Mazurier C
    Semin Thromb Hemost; 2006 Jul; 32(5):529-36. PubMed ID: 16862527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bleeding and clotting: new therapies and old issues revisited.
    Lee CA; Aledort LM
    Haemophilia; 2009 Mar; 15(2):592-6. PubMed ID: 19335754
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of inherited von Willebrand disease in 2007.
    Federici AB; Mannucci PM
    Ann Med; 2007; 39(5):346-58. PubMed ID: 17701477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [SD plasma safer than fresh-frozen plasma. Comparative studies show advantages of industrially produced plasma].
    Vaara I; Nilsson CD
    Lakartidningen; 2010 Jan 20-26; 107(3):106-7. PubMed ID: 20225684
    [No Abstract]   [Full Text] [Related]  

  • 6. [Menorrhagia and von Willebrand disease. Insufficient or incorrect treatment].
    Lysgaard D
    Ugeskr Laeger; 2001 Dec; 164(1):69. PubMed ID: 11810805
    [No Abstract]   [Full Text] [Related]  

  • 7. Late postpartum hemorrhage due to von Willebrand disease managed with uterine artery embolization.
    Salman MC; Cil B; Esin S; Deren O
    Obstet Gynecol; 2008 Feb; 111(2 Pt 2):573-5. PubMed ID: 18239026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pathogen inactivation in labile blood products: transfusion safety and economic impact].
    Cazenave JP
    Bull Acad Natl Med; 2006 Jan; 190(1):169-85; discussion 186-8. PubMed ID: 16878453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative management of a child with von Willebrand disease undergoing surgical repair of craniosynostosis: looking at unusual targets.
    Maquoi I; Bonhomme V; Born JD; Dresse MF; Ronge-Collard E; Minon JM; Hans P
    Anesth Analg; 2009 Sep; 109(3):720-4. PubMed ID: 19690238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Von Willebrand disease: a common and unrecognized bleeding disorder].
    Boehlen F; Robert-Ebadi H; de Moerloose P
    Rev Med Suisse; 2007 Feb; 3(97):346-50. PubMed ID: 17370733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Quality standards and quality control of plasma].
    Fürst G
    Beitr Infusionsther; 1991; 28():49-55. PubMed ID: 1725660
    [No Abstract]   [Full Text] [Related]  

  • 12. [Inborn and acquired von Willebrand disease].
    Schneppenheim R; Budde U
    Hamostaseologie; 2008 Dec; 28(5):312-9. PubMed ID: 19132162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemate P von Willebrand factor/factor VIII concentrate: 25 years of clinical experience.
    Schramm W
    Haemophilia; 2008 Nov; 14 Suppl 5():3-10. PubMed ID: 18786006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel.
    James AH; Kouides PA; Abdul-Kadir R; Edlund M; Federici AB; Halimeh S; Kamphuisen PW; Konkle BA; Martínez-Perez O; McLintock C; Peyvandi F; Winikoff R
    Am J Obstet Gynecol; 2009 Jul; 201(1):12.e1-8. PubMed ID: 19481722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease.
    De Meyer SF; Vandeputte N; Pareyn I; Petrus I; Lenting PJ; Chuah MK; VandenDriessche T; Deckmyn H; Vanhoorelbeke K
    Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1621-6. PubMed ID: 18556568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The quality of blood products in Mississippi takes another leap forward.
    Jett PL
    J Miss State Med Assoc; 1999 Nov; 40(11):390-1. PubMed ID: 10568090
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi a highly purified, doubly inactivated FVIII/VWF concentrate.
    Hernandez-Navarro F; Quintana M; Jimenez-Yuste V; Alvarez MT; Fernandez-Morata R
    Haemophilia; 2008 Sep; 14(5):963-7. PubMed ID: 18624696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Von Willebrand disease].
    Smejkal P; Matýsková M; Penka M
    Vnitr Lek; 2008 Mar; 54(3):257-64. PubMed ID: 18522294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of a universal, virus-inactivated and prion-depleted, pharmaceutical-quality plasma: a randomized, double-blind, clinical trial in healthy volunteers.
    Jilma-Stohlawetz P; Kursten FW; Walasek C; Horvath M; Leitner G; List J; Quehenberger P; Schwameis M; Bartko J; Jilma B
    Transfusion; 2011 Jun; 51(6):1228-40. PubMed ID: 21332722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and treatment of von Willebrand disease: new perspectives and nuances.
    Kessler CM
    Haemophilia; 2007 Dec; 13 Suppl 5():3-14. PubMed ID: 18078392
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.